Kuala Lumpur/Geneva – 25 November 2019
DNDi is pleased to announce a contribution of USD 2.2 million (9.2 million Malaysian Ringgit) from Malaysian pharmaceutical company, Pharmaniaga, to support the registration of a new treatment combination for people living with the hepatitis C virus in Malaysia.
Kuala Lumpur/Geneva – 25 November 2019
Geneva/Seattle – 25 November 2019
DNDi has been awarded $29.2 million to accelerate the development of innovative new drugs for patients in sub-Saharan Africa with sleeping sickness (human African trypanosomiasis – $15 million) and river blindness (onchocerciasis – $14.2 million) by the Bill & Melinda Gates Foundation These two parasitic diseases could be eliminated if new patient care tools are brought to bear.
29 November 2019
- This invitation-only event marks World AIDS Day and the end of DNDi’s multi-year Unitaid grant for the development and delivery of new paediatric HIV treatment formulations.
Paris, France – 18 October 2019
Bertrand Walckenaer, Deputy CEO of the Agence Française de Développement (AFD), and Dr Bernard Pécoul, Executive Director of DNDi, signed an agreement today for a project to support the research and development of treatments for neglected tropical diseases. Implementing a strategy to develop suitable, affordable, and safe treatments is a major international challenge; more than one billion people in 149 countries are affected by these diseases. This project is funded by a EUR 8 million grant.
Paris, France – le 18 octobre 2019
Bertrand Walckenaer, Directeur délégué de l’Agence française de développement, a signé, ce jour, avec Dr. Bernard Pécoul, Directeur exécutif de DNDi, un projet d’appui à la recherche et au développement de traitements contre les maladies tropicales négligées. La mise en place d’une stratégie de développement de traitements adaptés, abordables et sûrs est un enjeu majeur à l’échelle internationale : plus d’un milliard de personnes réparties dans 149 pays sont touchées par ces maladies. Le projet est une subvention d’un montant de 8 millions d’euros.
Mitsubishi Tanabe Pharma Corporation and DNDi are pleased to announce the financial support of the Global Health Innovative Technology (GHIT) Fund for their new discovery collaboration, with a grant of EUR 130’000/JPY 15 million.
Tribune de Genève [17 September 2019]
“La cuvée de la Vigne des Nations 2018 soigne une organisation internationale” – “The 2018 vintage of ‘La Vigne des Nations’ heals an international organization”
DNDi is pleased to announce a new partnership with Takeda Pharmaceutical Company Limited whose multi-year commitment was made through Takeda employees’ voting for Global Corporate Social Responsibility (CSR) Program 2019.
Health Policy Watch [5 February 2019]
“New funding partnership to develop innovative drugs for leishmaniasis”
London/Geneva – 5 February 2019
Wellcome has committed over £10 million to DNDi to develop new treatments for leishmaniasis, one of the world’s most devastating parasitic diseases. The three-year partnership will enable DNDi and Wellcome to develop new combinations of entirely new, all-orally acting chemical entities, through a joint strategy that also harnesses the strengths of the pharmaceutical and biotechnology industries, academia, and product development partnerships.
1 February 2019
A new research paper recently published by the AFD (Agence Française de Développement) examines how DNDi, a distinctive Product Development Partnership (PDP), can illustrate what can be presented as a “commons” in the area of public health.
TiaSáng [31 January 2019]
“Tài trợ cho nghiên cứu về những “căn bệnh bị lãng quên” tăng cao kỷ lục” – “Neglected disease research funding hits record high”
Mundiario [25 January 2019]
“La financiación de la investigación de enfermedades desatendidas alcanza un récord” – “Funding for research on neglected diseases reaches a record”
Nature [23 January 2019]
“Neglected disease research funding hits record high”
23 January 2019
The annual G-FINDER report provides policy-makers, donors, researchers, and industry with a comprehensive analysis of global investment into R&D of new products to prevent, diagnose, control, or cure neglected diseases in developing countries. It gives an up-to-date analysis of how R&D investments are being allocated across 33 neglected diseases, and product types, funding trends over time, and where the potential gaps lie.
Estadão [23 January 2019]
“Investimento do País em doenças negligenciadas cai 42% entre 2016 e 2017” – “Country investment in neglected diseases fell 42% between 2016 and 2017”
15 November 2018
On November 15, 2018, members of the Chagas Clinical Research Platform and the Global Chagas Coalition, participating in the VIII Meeting of the Chagas Platform in Santa Cruz de la Sierra, Bolivia, signed this letter addressed to governments, organizations and donors requesting an intensification in the efforts to control and eliminate Chagas disease as a public health problem. In the last 10 years, there have been significant efforts in the fight against the disease. However, many challenges remain. Next 2019 marks the 110th anniversary since the discovery of the disease and constitutes an opportunity to call attention to people affected by the disease and pursue necessary actions.
Healio [8 April 2018]
“International partnership invests $15.5 million to combat neglected tropical diseases, TB, malaria”
The Japanese pharmaceutical company Astellas Pharma Inc. is the eighth pharmaceutical company to join the Neglected Tropical Diseases Drug Discovery Booster, a global consortium launched in 2015 by DNDi to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease.